Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and ...

Analysts at HC Wainwright increased their Q1 2025 earnings estimates for shares of REGENXBIO in a note issued to investors on ...

Regenxbio (NASDAQ:RGNX) and Solid Biosciences (NASDAQ:SLDB) witnessed contrasting fortunes on Tuesday after Sarepta ...

REGENXBIO (RGNX) reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of ...

REGENXBIO (NASDAQ:RGNX – Free Report) had its price target cut by HC Wainwright from $36.00 to $34.00 in a research report ...

Barclays analyst Gena Wang maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price target of $50.00. The ...

Q4 2024 Earnings Call Transcript March 13, 2025 REGENXBIO Inc. beats earnings expectations. Reported EPS is $-1.01, ...

REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE® trial of RGX-202, a differentiated ...

(RTTNews) - REGENXBIO (RGNX) reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of RGX-202, a differentiated investigational ...

ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Regenxbio Inc. (RGNX) on Thursday reported a loss of $51.2 million in its fourth quarter. On a per-share basis, the Rockville, Maryland-based company said ...

Regenxbio Inc (RGNX) showcases robust financial positioning and strategic progress in gene therapy, despite challenges in cash reserves and competitive landscapes.

Welcome everyone to the Fourth Quarter and Year End 2024 REGENXBIO Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will ...